← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 2
Taxol (Taxol)
AstraZeneca·Non-small Cell Lung Cancer
ORR 36%
Overview
Program
Taxol
Overview
Company
AstraZeneca
Overview
Modality
CGT
Overview
Target
Non-small Cell Lung Cancer
Overview
Indication
Non-small Cell Lung Cancer
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
MoA
Mechanism
targeting epidermal growth factor receptor
MoA
Biomarker
biomarkers TRPM2 and SAMHD1, while upregulating tumor suppressors PRDM1, PCDHGB2, and ICAM1
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
Localization and Biological Activities of Bioflavonoids from Taxus canadensis Marshall.. Relict yew plants ( Taxus L.) are not only ornamental plants with valuable wood but also have the ability to synthesize the unique compound taxol, which is successfully used in the treatment of cancer due to its powerful cytotoxic effect. Due to the presence of taxol, all parts of yew plants are extremely pois…
Clinical
Primary efficacy
ORR 36%
Clinical
ORR
36%
Clinical
Result source
ClinicalTrials.gov NCT00462423
Clinical
Data Tier / Score
A · 44
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 13일 (1일 전)